Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

Agreement to Promote Development of Single-Use Biomass Sensors

By BiotechDaily International staff writers
Posted on 11 Mar 2013
A recently announced marketing and development agreement focuses on single-use biosensors that are used by the biopharmaceutical industry for obtaining in-line biomass measurements during cell cultivation and fermentation processes.

Sartorius Stedim Biothech (Aubagne, France), a leading provider of equipment and services for development, quality assurance, and production in the biopharmaceutical industry, will be cooperating with Aber Instruments (Aberystwyth, United Kingdom), a global leader in in-line biomass measurement technology. Biomass sensors are high-performance tools for modeling and optimizing biopharmaceutical development and manufacturing processes.

The agreement will give Sartorius exclusive global marketing and distribution rights to Aber's single-use sensor technology for the biopharmaceutical market. Sartorius will manufacture the biomass sensors under license, integrate these into its single-use bioreactors, and exclusively market these products in a dual-branding arrangement. New single-use sensors will be developed by both companies.

"Single-use sensors make our disposable bags even more intelligent," said Stefan Schlack, senior vice president of marketing at Sartorius Stedim Biothech. "They deliver real-time information about the progress of cell culture processes and help biopharmaceutical customers to understand their processes even better and further optimize them – a decisive competitive advantage."

Dr. John Carvell, sales and marketing director at Aber Instruments, said, "Based on Sartorius Stedim Biothech's global sales and distribution network, we can make our technology accessible to an even wider group of customers. Sartorius has in-depth expertise in single-use technology and is thoroughly versed in bioprocesses. Together with our profound knowledge of in-line biomass measurement, both companies stand to benefit from the joint development of new sensors.”

Related Links:

Sartorius Stedim Biothech
Aber Instruments




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.